Pune, India, September, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global Parry Romberg syndrome market.
According to the National Organization for Rare Disorder, Parry-Romberg syndrome is a rare and acquired disorder, which slowly shrink the skin and tissues of half of the face in most of the cases. In rare cases, both sides of the face are affected. In some cases, it may also affect the limbs usually on the same side of the body.
The global Parry-Romberg syndrome market is majorly driven by the increasing skin diseases patient population, increasing prevalence neurological disorders, and rapidly increasing demand for better diagnosis & treatment methods.
According to the Department of Economic and Social Affairs Population Division, globally, the number of adults aged over 60 years were 841 million in 2013, which increased the patient population of eye related diseases. Moreover, poor diet and lack of exercise have fuelled the prevalence of neurological disorders, which propels the market growth. However, high cost of the current treatment methods and lack of improved diagnosis methods may slow the growth of the market.
The Parry-Romberg Syndrome Market is expected to reach USD 923.3 Million by 2030 at 9.6% CAGR during the forecast period 2022-2030.
Taste the market data and market information presented through more than 125 market data tables and figures spread over 115 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Parry Romberg syndrome market research report–Global forecast till 2030.”
Major Players in the Parry-Romberg Syndrome Market
Some of the key players in the global market are DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland),Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd., Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.
Explore In-depth Details: Parry-Romberg Syndrome Market Research Report
The global Parry Romberg syndrome market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.
America accounts for the largest Parry-Romberg syndrome market owing to constantly increasing patient population of skin diseases, eye diseases, neurological disorder, and increasing government support for research.
Europe holds the second position in the market due to increasing development and more focus on healthcare domain. Countries such as Germany and France are investing more in research & development to develop new treatment methods for various skin diseases and eye disorder.
Asia Pacific is expected to be the fastest growing region for Parry-Romberg syndrome market. Increasing geriatric population, rising healthcare expenditure, and increasing prevalence of skin diseases drives the growth of the market. Moreover, developing countries such as India are focusing more on research & development by investing more in healthcare, which will boost the market growth.
On the other hand, the Middle East & Africa owns the least share of the Parry-Romberg syndrome market. The Middle East & Africa is expected witness the least market share due to less development in healthcare services such as new and advanced diagnosis & treatment methods in healthcare domain.
The global Parry-Romberg syndrome market is segmented on the basis of diagnosis, treatment, and end users.
On the basis of diagnosis, the market is segmented into physical examination, MRI, serum test, and other.
On the basis of treatment, the market is categorized into drug treatment, surgery, and others. Drug treatment is further segmented into methotrexate, corticosteroids, cyclophosphamide, and azathioprine, and other. Surgery segment is sub-segmented into orthognathic surgery, microsurgical reconstructive surgery, and others.
On the basis of end user, the market is segmented into hospitals & clinics, physical therapists, and others.